Resistance to conventional and target specific antitumor drugs still remains one of the major
cause of treatment failure and patience death. This condition often involves ATP-binding …

Tyrosine kinase inhibitors (TKIs) are anti‐cancer drugs that target tyrosine kinases, enzymes
that are involved in multiple cellular processes. Currently, multiple oral TKIs have been …

Highlights•Complete overview on exposure–response relationships for TKIs used in solid
tumors.•Dose individualization is expected to minimize toxicity and improve efficacy.•For …

Background: Plasma exposure of sunitinib shows large inter-individual variation. Therefore,
a pharmacokinetic (PK) study was performed to determine safety and feasibility of sunitinib …

Background In our exploratory studies, we associated single nucleotide polymorphisms
(SNPs) in candidate genes with the efficacy and toxicities of sunitinib in metastatic renal cell …

Interpatient variability in the pharmacokinetics (PK) of sunitinib is high. Single nucleotide
polymorphisms (SNPs) in PK candidate genes have been associated with the efficacy and …

Introduction: Co-medication, gene polymorphisms and co-morbidity are main causes for
high variability in expression and function of the CYP3A isoenzymes. Pharmacokinetic …

Introduction: Small molecule protein kinase inhibitors (KIs) are a class of drugs with complex
and unconventional physiochemical and pharmacokinetic characteristics. Cytochrome P450 …

Sunitinib is an orally administered tyrosine kinase inhibitor associated with idiosyncratic
hepatotoxicity; however, the mechanisms of this toxicity remain unclear. We have previously …

Background Vascular endothelial growth factor inhibitors (VEGFIs) are effective anticancer
agents which often induce hypertension. VEGFI-induced hypertension is sodium-sensitive in …